Kenneth S. Cohen to Chicago
This is a "connection" page, showing publications Kenneth S. Cohen has written about Chicago.
Connection Strength
0.049
-
University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL. Br J Haematol. 2018 04; 181(2):264-267.
Score: 0.026
-
Identifying early dropouts from a rehabilitation program for psychiatric outpatients. Psychiatr Serv. 1995 Oct; 46(10):1076-8.
Score: 0.023